Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol

Oncology Reports

Volumn 8, Issue 2, 2001, Pages 325-329

  Beech, Derrick J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Breast cancer; Doxorubicin; Insulin like growth factor I; Taxol

Indexed keywords

DOXORUBICIN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PACLITAXEL; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTICLE; BREAST TUMOR; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PACLITAXEL; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED;

EID: 0035286609     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.8.2.325     Document Type: Article

References (2)

1. Rowinsky EK, Casenavc LA and Donehower RC: Taxol a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990.
2. Rowinsky EK and Donehower RC: The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 20 (Suppl. 3): 16-25, 1993.